利用光片芯片设备对早期胚胎进行代谢成像的新应用:一项概念验证研究
本研究开发了一种光片芯片光流控设备,以小鼠两细胞期胚胎为模型,验证其获取烟酰胺腺嘌呤二核苷酸[NAD(P)H]自发荧光高分辨率三维代谢图像的安全性。结果显示光照组、未光照假对照组与对照组在囊胚形成率和胚胎质量上无显著差异,代谢图像预测囊胚形成的AUC为0.974。
要点
- 光片芯片设备可获取活体小鼠胚胎高分辨率三维NAD(P)H自发荧光代谢图像。
- 光照组、假对照组与对照组在囊胚形成率及胚胎质量上无显著差异(P>0.05)。
- 两细胞期胚胎代谢图像预测囊胚形成的AUC为0.974。
核心结论
- 光片芯片设备通过测量NAD(P)H自发荧光可产生活体胚胎代谢图像,提供了一种新颖且经济的方法。
- 两细胞期胚胎的代谢图像可预测囊胚形成,AUC为0.974。
研究设计与样本
- 概念验证研究,使用超数排卵F1(CBA/C57Bl6)小鼠产生两细胞期胚胎。
- 代谢成像后胚胎培养67小时,评估发育和活力(n=115),包括培养条件对照和未光照假对照。
- 免疫细胞化学评估囊胚质量,量化滋养外胚层和内细胞团细胞(n=75)。
- 胚胎培养期间评估代谢抑制(FK866抑制剂)(n=18)。
主要发现
- 设备可获取活体小鼠胚胎高分辨率三维图像,连续追踪胚胎位置,快速成像(<2秒),光照剂量为16 J·cm⁻²和8 J·cm⁻²。
- 适度光照剂量获得的图像信噪比是共聚焦系统的30倍(P<0.00001;t检验)。
- 对照组、光照组和未光照假对照组在胚胎发育和囊胚质量上无显著差异(P>0.05;Yate's卡方检验)。
- 代谢活性抑制的胚胎囊胚形成率较对照降低22.2%,代谢成像测量的代谢活性降低47%(P<0.0001;t检验)。
- 两细胞期胚胎代谢图像预测囊胚形成的AUC为0.974。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 研究使用小鼠模型,聚焦早期胚胎发育,评估两细胞期光照。
- 需进一步安全性研究,通过调查对活产率、子代健康、非整倍体率、突变负荷、基因表达变化和/或新生儿表观基因组稳定性任何潜在负面影响,评估405 nm光在囊胚期的安全性和使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it feasible to safely determine metabolic imaging signatures of nicotinamide adenine dinucleotide [NAD(P)H] associated auto-fluorescence in early embryos using a light-sheet on-a-chip approach? SUMMARY ANSWER: We developed an optofluidic device capable of obtaining high-resolution 3D images of the NAD(P)H autofluorescence of live mouse embryos using a light-sheet on-a-chip device as a proof-of-concept. WHAT IS KNOWN ALREADY: Selecting the most suitable embryos for implantation and subsequent healthy live birth is crucial to the success rate of assisted reproduction and offspring health. Besides morphological evaluation using optical microscopy, a promising alternative is the non-invasive imaging of live embryos to establish metabolic activity performance. Indeed, in recent years, metabolic imaging has been investigated using highly advanced microscopy technologies such as fluorescence-lifetime imaging and hyperspectral microscopy. STUDY DESIGN, SIZE, DURATION: The potential safety of the system was investigated by assessing the development and viability of live embryos after embryo culture for 67 h post metabolic imaging at the two-cell embryo stage (n = 115), including a control for culture conditions and sham controls (system non-illuminated). Embryo quality of developed blastocysts was assessed by immunocytochemistry to quantify trophectoderm and inner mass cells (n = 75). Furthermore, inhibition of metabolic activity (FK866 inhibitor) during embryo culture was also assessed (n = 18). PARTICIPANTS/MATERIALS, SETTING, METHODS: The microstructures were fabricated following a standard UV-photolithography process integrating light-sheet fluorescence microscopy into a microfluidic system, including on-chip micro-lenses to generate a light-sheet at the centre of a microchannel. Super-ovulated F1 (CBA/C57Bl6) mice were used to produce two-cell embryos and embryo culture experiments. Blastocyst formation rates and embryo quality (immunocytochemistry) were compared between the study groups. A convolutional neural network (ResNet 34) model using metabolic images was also trained. MAIN RESULTS AND THE ROLE OF CHANCE: The optofluidic device was capable of obtaining high-resolution 3D images of live mouse embryos that can be linked to their metabolic activity. The system's design allowed continuous tracking of the embryo location, including high control displacement through the light-sheet and fast imaging of the embryos (<2 s), while keeping a low dose of light exposure (16 J · cm-2 and 8 J · cm-2). Optimum settings for keeping sample viability showed that a modest light dosage was capable of obtaining 30 times higher signal-noise-ratio images than images obtained with a confocal system (P < 0.00001; t-test). The results showed no significant differences between the control, illuminated and non-illuminated embryos (sham control) for embryo development as well as embryo quality at the blastocyst stage (P > 0.05; Yate's chi-squared test). Additionally, embryos with inhibited metabolic activity showed a decreased blastocyst formation rate of 22.2% compared to controls, as well as a 47% reduction in metabolic activity measured by metabolic imaging (P < 0.0001; t-test). This indicates that the optofluidic device was capable of producing metabolic images of live embryos by measuring NAD(P)H autofluorescence, allowing a novel and affordable approach. The obtained metabolic images of two-cell embryos predicted blastocyst formation with an AUC of 0.974. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: The study was conducted using a mouse model focused on early embryo development assessing illumination at the two-cell stage. Further safety studies are required to assess the safety and use of 405 nm light at the blastocyst stage by investigating any potential negative impact on live birth rates, offspring health, aneuploidy rates, mutational load, changes in gene expression, and/or effects on epigenome stability in newborns. WIDER IMPLICATIONS OF THE FINDINGS: This light-sheet on-a-chip approach is novel and after rigorous safety studies and a roadmap for technology development, potential future applications could be developed for ART. The overall cost-efficient fabrication of the device will facilitate scalability and integration into future devices if full-safety application is demonstrated. STUDY FUNDING/COMPETING INTEREST(S): This work was partially supported by an Ideas Grant (no 2004126) from the National Health and Medical Research Council (NHMRC), by the Education Program in Reproduction and Development (EPRD), Department Obstetrics and Gynaecology, Monash University, and by the Department of Mechanical and Aerospace Engineering, Faculty of Engineering, Monash University. The authors E.V-O, R.N., V.J.C., A.N., and F.H. have applied for a patent on the topic of this technology (PCT/AU2023/051132). The remaining authors have nothing to disclose.
引用
- Vargas-Ordaz E, Newman H, Austin C, et al. Novel application of metabolic imaging of early embryos using a light-sheet on-a-chip device: a proof-of-concept study. Hum Reprod. 2025. PMID: 39521726. doi:10.1093/humrep/deae249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。